Immunopathogenesis of HIV/AIDS-related Oral Manifestations and Host Immunity (R21)

Post Date

September 8th 2011

Application Due Date

September 7th 2014

Funding Opportunity Number

PA-11-333

CFDA Number(s)

93.121

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Award Range:

  $None - $200000

Grant Description

This Funding Opportunity Announcement (FOA) issued by the National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health, encourages Exploratory/Developmental Research Grant applications that propose studies to translate new scientific insights about HIV infection, oral pathogen co-infections (viruses, bacteria and fungi) and AIDS-related oral opportunistic infections (viruses, bacteria, and fungi) into better understanding of the immunopathogenesis of these infectious agents to guide translational research focused on the development of novel, oral mucosal prophylactic HIV vaccines as well as therapeutic strategies against HIV, oral co-infections and oral opportunistic infections. The R21 mechanism intends to support early stages of high risk-high impact research that may lead to breaking new ground or extending previous discoveries.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PA-11-333.html